All tissues, sick and healthy alike, need a blood supply to survive and grow. The key to many medical problems, like preventing tumour development, is therefore to obstruct the spread of the blood vessels.
Should you leave your comfortable job for one that pays better but is less secure? Should you have a surgery that is likely to extend your life but poses some risk that you will not survive the operation?
Frost & Sullivan has awarded the COMPAS software technology platform its 2006 North America Technology Innovation of the Year Award in the field of Cardiac Safety Analytics.
US’ largest HIV/AIDS Healthcare provider says Pfizer?s direct-to-consumer ads for Viagra encourage recreational use and contributes to increased incidence of sexually transmitted diseases (STDs) including HIV.
Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Barr Laboratories, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Roche Laboratories Inc.’s KYTRIL(R) (granisetron hydrochloride) Tablets, 1mg (base).
Advanced Cell Technology, Inc., applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, has been awarded a research grant from the National Institutes of Health (NIH) in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners, The Burnham Institute of Medical Research (Burnham Institute).
HHS Secretary Mike Leavitt announced today that the department has awarded contracts totaling $132.5 million to three vaccine makers for the advanced development of H5N1 influenza vaccines using an immune system booster called an adjuvant. An adjuvant is a substance that may be added to a vaccine to increase the body?s immune response to the vaccine?s active ingredient, called antigen.
A drug based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs could be availiable by 2009. Vitamin D from sunlight improves the prognosis of certain cancers, but taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose.
Scientists at ProXara Biotechnology Limited have identified a way of switching off one of the key mechanisms that leads to the development and growth of a tumour. Under the Wellcome Trust’s Seeding Drug Discovery initiative, the researchers hope to use their findings to develop a drug that could be used to fight cancer. The funding will be used to develop the drug to a point at which it is close to entering a clinical trial.
A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need.